Search

Additional file 1: Table S1. Demographics and clinical characteristics of patients. Table S2. Primer sequences. Table S3. Primary antibodies. Table S4. Secondary antibodies. Table S5. ROC results of 47 autoantibodies. Table S6. Univariate and multivariate Cox regression analyses of factors associated with overall survival. Table S7. Univariate and multivariate Cox regression analyses of factors associated with progression-free survival. Table S8. Univariate and multivariate Cox regression analyses of factors associated with disease-free survival. Table S9. Univariate and multivariate Cox regression analyses of factors associated with disease-specific survival.

Additional file 2: Fig. S1. A WASF2 expression in matched pairs of patients with HCC from TCGA_LIHC, ICGC_LIRI, and GSE77314 datasets. B Differential expression of WASF2 in human hepatocarcinogenesis in GSE6764, GSE12443, and GSE114564 datasets (one-way ANOVA, post hoc comparisons, Tukey’s test). C Representative images of WASF2 expression in HCC tissues and D proportion of patients with different WASF2 immunostaining intensity in HCC specimens based on Human Protein Atlas (HPA) data. Scale bar = 200 μm. E Kaplan–Meier survival analyses of WASF2 expression in TCGA_LIHC datasets for overall survival (left), disease-specific survival (middle), and progression-free survival (right; log-rank test *P 0.3 or r